CN117695286A - 使用维贝隆以治疗膀胱过度活动症 - Google Patents

使用维贝隆以治疗膀胱过度活动症 Download PDF

Info

Publication number
CN117695286A
CN117695286A CN202311666042.4A CN202311666042A CN117695286A CN 117695286 A CN117695286 A CN 117695286A CN 202311666042 A CN202311666042 A CN 202311666042A CN 117695286 A CN117695286 A CN 117695286A
Authority
CN
China
Prior art keywords
vibelong
subject
dose
subjects
weeks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202311666042.4A
Other languages
English (en)
Chinese (zh)
Inventor
斯蒂芬·C·皮希泰利
保罗·马德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharmaceutical Suzhou Co Ltd
Original Assignee
Sumitomo Pharmaceutical Suzhou Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62815097&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN117695286(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sumitomo Pharmaceutical Suzhou Co Ltd filed Critical Sumitomo Pharmaceutical Suzhou Co Ltd
Publication of CN117695286A publication Critical patent/CN117695286A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN202311666042.4A 2017-06-06 2018-06-06 使用维贝隆以治疗膀胱过度活动症 Pending CN117695286A (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201762515996P 2017-06-06 2017-06-06
US62/515,996 2017-06-06
US201862635146P 2018-02-26 2018-02-26
US62/635,146 2018-02-26
US201862637961P 2018-03-02 2018-03-02
US62/637,961 2018-03-02
CN201880045540.8A CN110869022A (zh) 2017-06-06 2018-06-06 使用维贝隆以治疗膀胱过度活动症
PCT/IB2018/054069 WO2018224989A1 (en) 2017-06-06 2018-06-06 Use of vibegron to treat overactive bladder

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201880045540.8A Division CN110869022A (zh) 2017-06-06 2018-06-06 使用维贝隆以治疗膀胱过度活动症

Publications (1)

Publication Number Publication Date
CN117695286A true CN117695286A (zh) 2024-03-15

Family

ID=62815097

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202311666042.4A Pending CN117695286A (zh) 2017-06-06 2018-06-06 使用维贝隆以治疗膀胱过度活动症
CN202311666478.3A Pending CN117695287A (zh) 2017-06-06 2018-06-06 使用维贝隆以治疗膀胱过度活动症
CN201880045540.8A Pending CN110869022A (zh) 2017-06-06 2018-06-06 使用维贝隆以治疗膀胱过度活动症

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202311666478.3A Pending CN117695287A (zh) 2017-06-06 2018-06-06 使用维贝隆以治疗膀胱过度活动症
CN201880045540.8A Pending CN110869022A (zh) 2017-06-06 2018-06-06 使用维贝隆以治疗膀胱过度活动症

Country Status (14)

Country Link
US (2) US12102638B2 (https=)
EP (2) EP3634420A1 (https=)
JP (3) JP7682605B2 (https=)
KR (2) KR20200012949A (https=)
CN (3) CN117695286A (https=)
AU (2) AU2018282104B2 (https=)
BR (1) BR112019025636A2 (https=)
CA (1) CA3064989A1 (https=)
CL (1) CL2019003533A1 (https=)
IL (2) IL317220A (https=)
MX (1) MX2022015629A (https=)
PH (1) PH12019502651A1 (https=)
WO (1) WO2018224989A1 (https=)
ZA (1) ZA202000028B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102735800B1 (ko) * 2017-12-21 2024-11-28 교린 세이야쿠 가부시키가이샤 야간빈뇨 치료제
SG11202103662VA (en) * 2018-12-05 2021-06-29 Urovant Sciences Gmbh Vibegron for the treatment of overactive bladder symptoms
JP2022524576A (ja) * 2019-03-18 2022-05-09 ウロバント サイエンシズ ゲーエムベーハー 過活動膀胱を処置するためのビベグロンの使用
DE102020124101A1 (de) 2020-02-04 2021-08-05 Samsung Electronics Co., Ltd. Elektronische vorrichtung mit einer speichervorrichtung und trainingsverfahren
CA3202926A1 (en) * 2020-12-22 2022-06-30 Paul N. Mudd Jr. Methods of monitoring digoxin with concomitant use of vibegron to treat overactive bladder
WO2025262600A1 (en) 2024-06-17 2025-12-26 Urovant Sciences Gmbh Crystalline form of vibegron hemihydrate

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE266639T1 (de) 1997-10-17 2004-05-15 Yamanouchi Pharma Co Ltd Amidderivate oder deren salze
GB9812709D0 (en) 1998-06-13 1998-08-12 Glaxo Group Ltd Chemical compounds
US6562375B1 (en) 1999-08-04 2003-05-13 Yamanouchi Pharmaceuticals, Co., Ltd. Stable pharmaceutical composition for oral use
GB0015246D0 (en) * 2000-06-22 2000-08-16 Astrazeneca Ab Method for the treatment of urinary incontinence
US6525202B2 (en) 2000-07-17 2003-02-25 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
US7342117B2 (en) 2001-10-30 2008-03-11 Astellas Pharma Inc. α-form or β-form crystal of acetanilide derivative
DOP2003000587A (es) 2002-02-27 2003-08-30 Pfizer Prod Inc AGONISTAS DEL RECEPTOR ß3-ADRENERGICO
DK1559427T3 (da) 2002-11-07 2011-04-26 Astellas Pharma Inc Lægemiddel til overaktiv blære omfattende eddikesyreanilidderivat som den aktive bestanddel
DK1620085T3 (da) 2003-05-05 2008-11-24 Kissei Pharmaceutical Anvendelse af phenoxyacetatsyrederivater til behandling af hyperaktiv blære
FR2874011B1 (fr) 2004-08-03 2007-06-15 Sanofi Synthelabo Derives de sulfonamides, leur preparation et leur application en therapeutique
CA2682676A1 (en) 2007-04-19 2008-10-30 Novartis Ag Nicotinic acid derivatives as modulators of metabotropic glutamate receptor-5
EP2198018B1 (en) 2007-09-13 2013-11-20 Codexis, Inc. Ketoreductase polypeptides for the reduction of acetophenones
CA2704298C (en) 2007-11-02 2015-07-21 Astellas Pharma Inc. Pharmaceutical composition for treating overactive bladder
PE20091825A1 (es) 2008-04-04 2009-12-04 Merck & Co Inc Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3
US8273554B2 (en) 2008-08-29 2012-09-25 Codexis, Inc. Ketoreductase polypeptides for the stereoselective production of (4S)-3-[(5S)-5-(4-fluorophenyl)-5-hydroxypentanoyl]-4-phenyl-1,3-oxazolidin-2-one
WO2011043942A1 (en) 2009-10-07 2011-04-14 Merck Sharp & Dohme Corp. Combination therapy using a beta 3 adrenergic receptor agonist and an antimuscarinic agent
WO2011137054A1 (en) 2010-04-30 2011-11-03 Merck Sharp & Dohme Corp. Novel beta 3 adrenergic receptor agonists
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
US9522129B2 (en) 2010-08-03 2016-12-20 Velicept Therapeutics, Inc. Pharmaceutical Combination
AU2011285928B9 (en) 2010-08-03 2018-08-02 B3Ar Therapeutics, Inc. Combinations of beta - 3 adrenergic receptor agonists and muscarinic receptor antagonists for treating overactive bladder
AU2012323890A1 (en) 2011-10-14 2014-05-29 Array Biopharma Inc. Polymorphs of arry-380, a selective ErbB2 inhibitor and pharmaceutical compositions containing them
ES2584427T3 (es) 2011-10-27 2016-09-27 Merck Sharp & Dohme Corp. Proceso para la preparación de agonistas beta 3 y productos intermedios
WO2013062881A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Process for making beta 3 agonists and intermediates
IN2014CN04470A (https=) 2011-11-18 2015-09-04 Codexis Inc
EP2606894A1 (en) 2011-12-20 2013-06-26 Sanofi Novel therapeutic use of p75 receptor antagonists
UA112028C2 (uk) 2012-12-14 2016-07-11 Пфайзер Лімітед Похідні імідазопіридазину як модулятори гамка-рецептора
RS59402B1 (sr) 2013-03-15 2019-11-29 Merck Sharp & Dohme Postupak za pripremu beta 3 agonista i međuproizvoda
HK1245117A1 (zh) 2014-12-03 2018-08-24 Velicept Therapeutics, Inc. 使用调节释放索拉贝隆用於下尿路症状的组合物和方法
ES2967863T3 (es) 2015-10-23 2024-05-06 B3Ar Therapeutics Inc Ion dipolar de solabegron y usos del mismo
US20170348288A1 (en) 2016-06-03 2017-12-07 Velicept Therapeutics, Inc. Dosing regimens for beta-3 adrenoceptor agonists and anti-muscarinic agents for the treatment and prevention of lower urinary tract symptoms and overactive bladder
EP3463307A4 (en) 2016-06-03 2020-01-15 Velicept Therapeutics, Inc. COMPOSITIONS AND METHODS FOR USE OF SOLABEGRON WITH MODIFIED RELEASE FOR SYMPTOMS OF THE LOWER URINARY PATHWAYS
JP7670461B2 (ja) 2017-06-06 2025-04-30 ウロバント サイエンシズ ゲゼルシャフト ミット ベシュレンクター ハフトゥング 過活動膀胱の治療のためのビベグロンの投薬
KR102735800B1 (ko) 2017-12-21 2024-11-28 교린 세이야쿠 가부시키가이샤 야간빈뇨 치료제
SG11202010683PA (en) 2018-05-23 2020-12-30 Urovant Sciences Gmbh Use of vibegron to treat pain associated with irritable bowel syndrome
SG11202103662VA (en) 2018-12-05 2021-06-29 Urovant Sciences Gmbh Vibegron for the treatment of overactive bladder symptoms
JP2022524576A (ja) 2019-03-18 2022-05-09 ウロバント サイエンシズ ゲーエムベーハー 過活動膀胱を処置するためのビベグロンの使用
CA3202926A1 (en) 2020-12-22 2022-06-30 Paul N. Mudd Jr. Methods of monitoring digoxin with concomitant use of vibegron to treat overactive bladder
TW202245781A (zh) 2021-02-16 2022-12-01 瑞士商優洛凡特科學公司 用維貝格龍（ｖｉｂｅｇｒｏｎ）治療心臟衰竭之方法

Also Published As

Publication number Publication date
US20210077495A1 (en) 2021-03-18
IL271164A (en) 2020-01-30
CN110869022A (zh) 2020-03-06
MX2022015629A (es) 2023-01-11
US20260014158A1 (en) 2026-01-15
JP2025063196A (ja) 2025-04-15
JP2020522560A (ja) 2020-07-30
ZA202000028B (en) 2025-09-25
WO2018224989A1 (en) 2018-12-13
JP2023071826A (ja) 2023-05-23
CL2019003533A1 (es) 2020-06-26
AU2018282104B2 (en) 2024-07-11
JP7682605B2 (ja) 2025-05-26
KR20250099259A (ko) 2025-07-01
EP4410295A3 (en) 2024-10-16
AU2024204591A1 (en) 2024-07-18
IL317220A (en) 2025-01-01
US12102638B2 (en) 2024-10-01
EP4410295A2 (en) 2024-08-07
CA3064989A1 (en) 2018-12-13
AU2018282104A1 (en) 2019-12-12
CN117695287A (zh) 2024-03-15
PH12019502651A1 (en) 2020-06-08
BR112019025636A2 (pt) 2020-08-25
EP3634420A1 (en) 2020-04-15
KR20200012949A (ko) 2020-02-05

Similar Documents

Publication Publication Date Title
US20260014158A1 (en) Use of vibegron to treat overactive bladder
US20230218624A1 (en) Dosing of vibegron for treatment of overactive bladder
TWI402083B (zh) 固形製劑及其安定化方法
AU2019393372B2 (en) Vibegron for the treatment of overactive bladder symptoms
AU2019273837A1 (en) Use of vibegron to treat pain associated with irritable bowel syndrome
TWI488658B (zh) 溶出性之改善方法
HK40114255A (en) Use of vibegron to treat overactive bladder
EA045454B1 (ru) Применение вибегрона для лечения гиперактивного мочевого пузыря
JP2011225537A (ja) 固形製剤の製造方法
HK40126413A (en) Use of vibegron to treat overactive bladder symptoms in men with benign prostatic hyperplasia

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination